TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., Nov. 13, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance
How this was made
The 30-second read
Why it matters
The combination of financial results and early clinical data creates a fresh catalyst that could move the stock in the short term.
Market read
New trial data and FDA clearance are material for HURA shareholders and may influence biotech sector sentiment.
What to watch
Potential dilution from future financing rounds and the need for accelerated approval pathways could weigh on valuation.
TuHURA reports Q3 2026 R&D of $3.7 million and G&A of $2.0 million, with $1.9 million cash at September 30, 2026, and funding from the Parkview credit facility
The release reports $1.9 million of cash at September 30, 2026, against nine-month operating cash outflows of ($18.1) million. Funding came from the Parkview credit facility ($9.2 million gross proceeds to date). Clinical and patent milestones were reported, but the filing gives no revenue and no net loss, so the financial position cannot be assessed beyond cash and cash flow.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, 3 months ended September 30, 2026other | $3.7M | – | decrease of $1.3 million |
| General and administrative expenses, 3 months ended September 30, 2026other | $2M | – | increase of $0.4 million |
| Net cash outflows from operating activities, 9 months ended September 30, 2026other | ($18.1) million | – | – |
| Net cash flows from financing activities, 9 months ended September 30, 2026other | $16.5M | – | – |
| Cash and cash equivalents at September 30, 2026other | $1.9M | – | – |
| Parkview credit facility gross proceeds received as of September 30, 2026other | $9.2M | – | – |
| Parkview loan facility non-dilutive financing contributed during the quarter ended September 30, 2026other | $5.6M | – | – |
Capital returns
- The release reports no share repurchases and no dividends.
- The CEO states the company has continuing access to a $50mm credit facility from its largest shareholder, which it describes as funding operations in a non-dilutive manner.
- The Parkview loan facility contributed $5.6 million in non-dilutive financing during the quarter ended September 30, 2026, and gross proceeds on the facility were $9.2 million as of September 30, 2026.
What drove it
- The company states that R&D decreased by $1.3 million due to lower manufacturing costs, and that these costs are expected to resume in the next quarter with the start of the TBS-2025 clinical trial material manufacturing campaign.
- The company states that G&A increased by $0.4 million, primarily due to increases in non-cash stock compensation expense and costs associated with being a public company.
- Financing inflows over the 9 months are described as coming from the Parkview credit facility, with gross proceeds of $9.2 million received as of September 30, 2026.
Concerns
- Cash of $1.9 million at September 30, 2026 is small relative to nine-month operating cash outflows of ($18.1) million, and the company relies on credit facility funding to run operations.
- The forward-looking statements list the risk that funds available under the credit facility may be insufficient to fund operations and development programs to the extent anticipated.
- The company's own explanation for lower R&D is lower manufacturing costs, which the release says are expected to resume next quarter. The R&D figure may therefore rise in the next quarter.
- The release has an internal inconsistency on the TBS-2025 trial design. The corporate update describes a Phase 1b study, while the milestone list describes a Phase 1b/2 trial to be initiated in 2H 2026.
- The release gives no revenue, gross margin, net loss, or EPS, so the income statement cannot be assessed from this filing.
What to watch
- Resumption of TBS-2025 clinical trial material manufacturing in the next quarter, and the R&D expense level that follows.
- Initiation of the TBS-2025 Phase 1b/2 trial in mutated NPM1 r/r AML, targeted for 2H 2026.
- Orphan drug designation in MCC, expected 2H 2026.
- Three ASH poster presentations on DOR technology, scheduled for December 12-15, 2026 in New Orleans.
- Preliminary results from the front-line IFx-2.0 study with Keytruda in MCC, expected 1H 2027.
- Remaining availability under the Parkview facility and the $50mm credit facility from the largest shareholder, relative to operating cash needs.
- Preliminary safety and response data for VISTA in mutated NPM1 r/r AML, expected 1H 2027.
Balance sheet and cash flow
- Cash and cash equivalents were $1.9 million at September 30, 2026. No prior-period cash balance is printed in the release.
- Net cash outflows from operating activities were ($18.1) million for the 9 months ended September 30, 2026, compared with ($22.1) million for the 9 months ended September 30, 2025.
- Net cash flows from financing activities were $16.5 million for the 9 months ended September 30, 2026, compared with $13.4 million for the 9 months ended September 30, 2025.
- Total common shares outstanding were approximately 65.8 million at September 30, 2026.
- The release does not print total assets, total liabilities, stockholders' equity, or the outstanding principal balance of the Parkview facility.
Analysis
TuHURA's Q3 2026 release is a corporate and clinical update with a short set of financial figures. It reports Q3 2026 R&D expenses of $3.7 million against $5.0 million in Q3 2025, and G&A expenses of $2.0 million against $1.6 million. The company attributes the R&D decrease to lower manufacturing costs and says those costs are expected to resume next quarter with the start of the TBS-2025 clinical trial material manufacturing campaign. It attributes the G&A increase primarily to non-cash stock compensation and public company costs. The filing does not print revenue, gross margin, operating loss, net loss, or EPS, so the income statement cannot be analyzed beyond these two expense lines.
The cash position is the central financial data point. Cash and cash equivalents were $1.9 million at September 30, 2026. Net cash outflows from operating activities were ($18.1) million for the nine months ended September 30, 2026, compared with ($22.1) million for the nine months ended September 30, 2025. Net cash inflows from financing activities were $16.5 million for the nine months, compared with $13.4 million a year earlier. The company states that $9.2 million in gross proceeds had been received on the Parkview credit facility as of September 30, 2026, and that the facility contributed $5.6 million during the quarter. The CEO refers to continuing access to a $50mm credit facility from the largest shareholder. The forward-looking statements list the risk that credit facility funds may be insufficient to fund operations and development programs as anticipated.
On the programs, the release reports three ASH poster presentations on Delta Opioid Receptor technology for December 12-15, 2026, a first look at IFx-2.0 data in front-line metastatic Merkel cell carcinoma (major objective partial responses in the first three patients, ongoing for more than six months), a new U.S. patent for TBS-2025 extending to 2042, a key U.S. patent for the DOR antibody drug conjugate platform running through 2043, and FDA clearance for a Phase 1b study of TBS-2025 in relapsed/refractory mut NPM1 AML. The milestone list calls the TBS-2025 study a Phase 1b/2 trial, while the corporate text calls it a Phase 1b study. The release does not print any prior-period milestone status, so changes against the earlier quarter cannot be measured.
Capital allocation in the period consisted of financing, not returns. The release reports no share repurchases or dividends and shows approximately 65.8 million common shares outstanding at September 30, 2026. The prior-year and prior-quarter comparatives for cash, debt, and total equity are not printed, so balance sheet trends cannot be measured. Readers should weigh the $1.9 million cash balance and the reliance on credit facility funding against the stated clinical milestones for the second half of 2026 and first half of 2027.
Management, verbatim
With meaningful progress having been made in each of our programs, we believe we are well positioned to deliver on several transformational potential milestones. Having continuing access to a $50mm credit facility from our largest shareholder has allowed us to fund operations in a non-dilutive manner benefiting shareholders as we continue driving towards these value-creating events,
Dr. James Bianco, President and Chief Executive Officer, TuHURA Biosciences
Working collaboratively with the FDA, we received clearance to begin our Phase 1b study of TBS-2025, our VISTA-inhibiting antibody, in relapsed/refractory mut NPM1 acute myeloid leukemia (AML), a molecularly defined subset of AML where the presence of VISTA on leukemic cells is associated with poor response to therapy and survival.
Dr. James Bianco, President and Chief Executive Officer, TuHURA Biosciences
In October, we shared our first look at data from our open-label front line study of IFx-2.0 with Keytruda® in patients with deep-seated metastatic Merkel cell carcinoma, which showed durable, major objective anti-tumor responses in the first three patients with all responses ongoing for more than six months,
Dr. James Bianco, President and Chief Executive Officer, TuHURA Biosciences
Not in the filing
stated, not guessed- Total revenue or license revenue for Q3 2026 and prior periods (not printed; the release gives no revenue line).
- Gross margin and cost of sales (not printed).
- Operating loss, total operating expenses, and net loss for Q3 2026 and prior periods (not printed).
- Net loss per share, GAAP or otherwise (not printed).
- Interest expense and income tax (not printed).
- Prior-quarter (Q2 2026) values for R&D, G&A, and cash (not printed).
- Nine-month R&D and G&A figures for 2026 and 2025 (not printed).
- Percentage changes for R&D and G&A (only dollar changes are printed).
- Total assets, total liabilities, and stockholders' equity (not printed).
- Outstanding principal balance of the Parkview facility and the terms of the $50mm facility (not printed).
- Prior-year cash balance at September 30, 2025 (not printed).
- Statement of whether the financial figures are GAAP or non-GAAP (not stated; basis set to other).
- Financial guidance for 2026 or 2027 (none printed).
- Prior-period outlook for comparison (no previous release was provided).
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The filing is a standard SEC 8‑K quarterly report for a micro‑cap biotech, providing both financial metrics and updates on its lead immunotherapy programs.
Ticker impact
TuHURA Biosciences filed an 8‑K reporting Q3 2026 financial results and disclosed first‑look data from its IFx‑2.0 study and FDA clearance for its TBS‑2025 VISTA‑inhibiting antibody.
likely modest upside as investors price in encouraging clinical progress
The disclosed data are new and material for a biotech; markets typically react positively to early efficacy signals and FDA clearance, though cash constraints temper the rally.
Market effects
Early immuno‑oncology data could boost interest in the broader checkpoint‑inhibitor and VISTA‑targeted therapy space.
Primarily affects US‑listed biotech investors; limited immediate impact on broader markets.
Adds to the pipeline momentum of biotech firms developing resistance‑overcoming immunotherapies worldwide.
Counterpoint
Cash runway is tight and the data set is very small (3 patients); investors may remain cautious until larger cohorts report.
Key entities
- companyTuHURA Biosciences, Inc.
Phase‑3 immuno‑oncology company developing IFx‑2.0 and TBS‑2025.
- executiveDr. James Bianco
President and CEO of TuHURA, quoted on trial progress.



